| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody
|
Tomita, Y.
|
|
|
28 |
11 |
p. 2893-2895
|
artikel
|
| 2 |
Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium
|
Giraldi, L.
|
|
|
28 |
11 |
p. 2843-2851
|
artikel
|
| 3 |
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD,NPM1- or biallelicCEBPA mutations
|
Heidrich, K.
|
|
|
28 |
11 |
p. 2793-2798
|
artikel
|
| 4 |
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma
|
Temam, S.
|
|
|
28 |
11 |
p. 2827-2835
|
artikel
|
| 5 |
An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients
|
Koller, M.
|
|
|
28 |
11 |
p. 2874-2881
|
artikel
|
| 6 |
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)
|
Martin, P.
|
|
|
28 |
11 |
p. 2806-2812
|
artikel
|
| 7 |
A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study
|
Chajès, V.
|
|
|
28 |
11 |
p. 2836-2842
|
artikel
|
| 8 |
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
|
Fizazi, K.
|
|
|
28 |
11 |
p. 2741-2746
|
artikel
|
| 9 |
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
|
Voss, M.H.
|
|
|
28 |
11 |
p. 2754-2760
|
artikel
|
| 10 |
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
|
Bossi, P.
|
|
|
28 |
11 |
p. 2820-2826
|
artikel
|
| 11 |
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
|
Sanz-Garcia, E.
|
|
|
28 |
11 |
p. 2648-2657
|
artikel
|
| 12 |
Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors
|
Sellami, D.
|
|
|
28 |
11 |
p. 2882-2887
|
artikel
|
| 13 |
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial
|
Park, S.B.
|
|
|
28 |
11 |
p. 2733-2740
|
artikel
|
| 14 |
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
|
Leduc, C.
|
|
|
28 |
11 |
p. 2715-2724
|
artikel
|
| 15 |
Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma
|
Magnano, L.
|
|
|
28 |
11 |
p. 2799-2805
|
artikel
|
| 16 |
Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”
|
Cherny, N.I.
|
|
|
28 |
11 |
p. 2901-2905
|
artikel
|
| 17 |
Corrections to “Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?”
|
Santini, D.
|
|
|
28 |
11 |
p. 2906
|
artikel
|
| 18 |
Corrections to “Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression” † † Presented in part at the 31st (10–14 December 2008), and at the 33rd (8–12 December 2010) Annual San Antonio Breast Cancer Symposium San Antonio, TX, and at the 44th Annual Meeting of the American Society of Clinical Oncology (30 May–03 June 2008), Chicago, IL, USA.
|
Nitz, U.
|
|
|
28 |
11 |
p. 2899
|
artikel
|
| 19 |
Corrections to “SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study”
|
Sinn, M.
|
|
|
28 |
11 |
p. 2900
|
artikel
|
| 20 |
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
|
Nitz, U.A.
|
|
|
28 |
11 |
p. 2768-2772
|
artikel
|
| 21 |
Editorial Board
|
|
|
|
28 |
11 |
p. i-ii
|
artikel
|
| 22 |
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial
|
Miles, D.
|
|
|
28 |
11 |
p. 2761-2767
|
artikel
|
| 23 |
Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer
|
Ohgami, M.
|
|
|
28 |
11 |
p. 2888-2889
|
artikel
|
| 24 |
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
|
Cherny, N.I.
|
|
|
28 |
11 |
p. 2633-2647
|
artikel
|
| 25 |
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy
|
McCoach, C.E.
|
|
|
28 |
11 |
p. 2707-2714
|
artikel
|
| 26 |
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy
|
Saad, E.D.
|
|
|
28 |
11 |
p. 2629-2630
|
artikel
|
| 27 |
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol
|
Bernichon, E.
|
|
|
28 |
11 |
p. 2773-2779
|
artikel
|
| 28 |
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
|
Chung, J.H.
|
|
|
28 |
11 |
p. 2866-2873
|
artikel
|
| 29 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
|
Berger, M.D.
|
|
|
28 |
11 |
p. 2780-2785
|
artikel
|
| 30 |
Improved survival using specialized multidisciplinary board in sarcoma patients
|
Blay, J.-Y.
|
|
|
28 |
11 |
p. 2852-2859
|
artikel
|
| 31 |
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
|
Collins, M.
|
|
|
28 |
11 |
p. 2860-2865
|
artikel
|
| 32 |
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer
|
Ciuffreda, L.
|
|
|
28 |
11 |
p. 2896-2898
|
artikel
|
| 33 |
Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients
|
Penel, N.
|
|
|
28 |
11 |
p. 2891-2893
|
artikel
|
| 34 |
Long-term toxicity of cisplatin in germ-cell tumor survivors
|
Chovanec, M.
|
|
|
28 |
11 |
p. 2670-2679
|
artikel
|
| 35 |
Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective
|
Reddy, N.M.
|
|
|
28 |
11 |
p. 2680-2690
|
artikel
|
| 36 |
Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy
|
Trone, J.C.
|
|
|
28 |
11 |
p. 2691-2697
|
artikel
|
| 37 |
Nivolumab-induced asthma in a patient with non-small-cell lung cancer
|
Maeno, K.
|
|
|
28 |
11 |
p. 2891
|
artikel
|
| 38 |
Nivolumab in HIV-related non-small-cell lung cancer
|
Hentrich, M.
|
|
|
28 |
11 |
p. 2890
|
artikel
|
| 39 |
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
|
Schlumberger, M.
|
|
|
28 |
11 |
p. 2813-2819
|
artikel
|
| 40 |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
|
Nokihara, H.
|
|
|
28 |
11 |
p. 2698-2706
|
artikel
|
| 41 |
Reply to the letter to the editor ‘Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer’ by Sciallero et al.
|
Dienstmann, R.
|
|
|
28 |
11 |
p. 2889-2890
|
artikel
|
| 42 |
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools
|
Giovannetti, E.
|
|
|
28 |
11 |
p. 2725-2732
|
artikel
|
| 43 |
S-1 as an option for second-line treatment of NSCLC. Is the ‘East Side Story’ applicable in the West?
|
Hayashi, H.
|
|
|
28 |
11 |
p. 2627-2629
|
artikel
|
| 44 |
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
|
Reni, M.
|
|
|
28 |
11 |
p. 2786-2792
|
artikel
|
| 45 |
Table of Contents
|
|
|
|
28 |
11 |
p. iii-vi
|
artikel
|
| 46 |
The evolution of chemotherapy for the treatment of prostate cancer
|
Quinn, D.I.
|
|
|
28 |
11 |
p. 2658-2669
|
artikel
|
| 47 |
The past and future of ‘reported outcomes’ in studies on chemotherapy neuropathy
|
Beutler, A.S.
|
|
|
28 |
11 |
p. 2631-2632
|
artikel
|
| 48 |
Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration
|
Wu, C.-K.
|
|
|
28 |
11 |
p. 2895-2896
|
artikel
|
| 49 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population
|
Buti, S.
|
|
|
28 |
11 |
p. 2747-2753
|
artikel
|
Tijdschrift beschrijving